Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joan-Carles Reverter

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Journal of Hepatology|December 12, 2022
Reply to: "Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis"Anna Baiges, Joan Carles Reverter, Joan Carles García Pagán
Medicina Clinica|January 29, 2008
[Bilateral suprarenal hematoma in a 46-year-old male]Mónica Rodríguez Carballeira, Carmen de Juan, Joan Carles Reverter
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|November 5, 2005
No impact of factor IX Ala-10 mutations in acenocoumarol-treated southern EuropeansDolors Tàssies, Joan Monteagudo, Santiago Maragall, et al.
Analytica Chimica Acta|June 10, 2018
Enzyme-linked immunosorbent assays for therapeutic drug monitoring coumarin oral anticoagulants in plasmaJ-Pablo Salvador, Dolors Tassies, Joan-Carles Reverter, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|October 17, 2006
Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatmentRonald A Asherson, Gerard Espinosa, Ricard Cervera, et al.
Clinical and Experimental Rheumatology|July 29, 2014
Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapyJuan-Carlos Mejía, Gerard Espinosa, Dolors Tàssies, et al.
The Israel Medical Association Journal : IMAJ|August 20, 2002
Vascular involvement in Behçet's diseaseGerard Espinosa, Ricard Cervera, Joan-Carles Reverter, et al.
Haematologica|November 5, 2002
Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulationDolors Tàssies, Carolina Freire, Josefina Pijoan, et al.
Rheumatology (Oxford, England)|November 26, 2020
Comment on: EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodiesGilberto Pires da Rosa, Paulo Bettencourt, Ester Ferreira, et al.
International Journal of Cardiology|January 29, 2009
Safety issues of adjunctive clopidogrel in patients discharged after percutaneous coronary intervention with stent placement and requiring oral anticoagulationEduard Guasch, Alessandro Sionis, Joan Carles Reverter, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Journal of Hepatology|December 12, 2022
Reply to: "Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis"Anna Baiges, Joan Carles Reverter, Joan Carles García Pagán
Medicina Clinica|January 29, 2008
[Bilateral suprarenal hematoma in a 46-year-old male]Mónica Rodríguez Carballeira, Carmen de Juan, Joan Carles Reverter
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|November 5, 2005
No impact of factor IX Ala-10 mutations in acenocoumarol-treated southern EuropeansDolors Tàssies, Joan Monteagudo, Santiago Maragall, et al.
Analytica Chimica Acta|June 10, 2018
Enzyme-linked immunosorbent assays for therapeutic drug monitoring coumarin oral anticoagulants in plasmaJ-Pablo Salvador, Dolors Tassies, Joan-Carles Reverter, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|October 17, 2006
Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatmentRonald A Asherson, Gerard Espinosa, Ricard Cervera, et al.
Clinical and Experimental Rheumatology|July 29, 2014
Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapyJuan-Carlos Mejía, Gerard Espinosa, Dolors Tàssies, et al.
The Israel Medical Association Journal : IMAJ|August 20, 2002
Vascular involvement in Behçet's diseaseGerard Espinosa, Ricard Cervera, Joan-Carles Reverter, et al.
Haematologica|November 5, 2002
Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulationDolors Tàssies, Carolina Freire, Josefina Pijoan, et al.
Rheumatology (Oxford, England)|November 26, 2020
Comment on: EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodiesGilberto Pires da Rosa, Paulo Bettencourt, Ester Ferreira, et al.
International Journal of Cardiology|January 29, 2009
Safety issues of adjunctive clopidogrel in patients discharged after percutaneous coronary intervention with stent placement and requiring oral anticoagulationEduard Guasch, Alessandro Sionis, Joan Carles Reverter, et al.
Pageof 5